Rocky history of Illumina’s Grail deal
(Reuters) – Gene-sequencing machine maker Illumina Inc has filed an appeal against an order from the U.S. Federal Trade Commission (FTC) that demands it divest cancer diagnostic test maker Grail Inc on competition concerns. Illumina spun off Grail in 2016, but retained a 12% stake. It reacquired the cancer test maker in 2021, despite opposition…